Skip to main content
curacle co., ltd. logo

curacle co., ltd. — Investor Relations & Filings

Ticker · 365270 ISIN · KR7365270008 KO Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 365270

About curacle co., ltd.

http://www.curacle.com/eng/main/

Curacle Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs for intractable vascular diseases. The company's core platform technology centers on developing highly effective protectors against endothelial dysfunction, a key factor in various age-related and vascular conditions. Its development pipeline includes novel treatments targeting significant unmet medical needs, with a particular focus on conditions such as Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (wet AMD), diabetes, and stroke. Curacle aims to create differentiated therapies through innovative targets and treatment concepts, including the development of orally administered medications for complex eye diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 90% confidence The document is titled “분기보고서 (제11기) 2026년 01월 01일~2026년 03월 31일” and contains a full set of company disclosures, business overview, pipeline details, capital structure, and will include financial statements for the quarter. This corresponds to a comprehensive quarterly (interim) report with substantive financial and narrative content. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항 (이중항체 MT103 기술이전 계약 체결)
Regulatory Filings Classification · 72% confidence The document is a Korean stock exchange regulatory disclosure reporting the signing of a major technology‐transfer contract (MT‐103 double antibody license agreement). It is a mandatory announcement of a material business contract affecting investment decisions, not a full financial report or earnings release. It does not present financial statements but simply discloses key contract terms. This falls under “Regulatory Filings (RNS)” as a general regulatory announcement for miscellaneous filings, since no more specific category applies.
2026-05-11 Korean
투자판단관련주요경영사항(임상시험결과) (CU011001 당뇨병성 신증치료제 식품의약품안전처 임상 2b상 CSR 결과)
Regulatory Filings Classification · 75% confidence The document is a short Korean disclosure of clinical trial results (“투자판단 관련 주요경영사항(임상시험 결과)”) with tables of trial design and data. It is an operational update regarding a drug development trial, not an earnings release, financing or board change. It does not present full financial statements (10-K/IR), management discussion of financial results (MDA), or an investor slide deck (IP). It is a standalone regulatory announcement that does not fit any more specific category, making "Regulatory Filings" (RNS) the appropriate fallback.
2026-04-02 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “정기주주총회결과” (Ordinary Shareholders’ Meeting Results) with detailed vote outcomes for each agenda item, including approval of financial statements, director remuneration, and amendments to business objectives. It clearly reports voting results from an AGM. According to the filing definitions, this corresponds to “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a statutory notification to the Financial Services Commission/Korea Exchange regarding the grant of stock purchase options (stock options) to directors and employees, detailing terms, exercise price, quantities and related capital provisions. This is not an earnings report, management change announcement, or a meeting material; rather it constitutes a corporate action affecting the share capital structure (granting subscription rights to new shares). Therefore it best fits the "Share Issue/Capital Change" category (SHA).
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from the company Curacle. It provides the auditor's opinion (unqualified/proper), financial highlights (assets, liabilities, revenue, profit/loss), and details regarding capital impairment and operating losses for the fiscal year ending 2025-12-31. While it contains audit-related information, it is a standard regulatory disclosure of the audit results rather than the full, multi-page audit report document itself. Given the structure and content, it fits the 'Audit Report / Information' (AR) category as it provides the specific audit opinion and financial data required by regulatory bodies. FY 2025
2026-03-18 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.